发病率的问题:对全球报道的药物相关性颌骨骨坏死(MRONJ)发病率的范围审查。

BMJ public health Pub Date : 2025-04-05 eCollection Date: 2025-01-01 DOI:10.1136/bmjph-2024-002009
Ailish Suzanne Emuss Clark, Anne-Marie Glenny
{"title":"发病率的问题:对全球报道的药物相关性颌骨骨坏死(MRONJ)发病率的范围审查。","authors":"Ailish Suzanne Emuss Clark, Anne-Marie Glenny","doi":"10.1136/bmjph-2024-002009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Medication-related osteonecrosis of the jaws (MRONJ) can be a debilitating condition which is challenging to manage. While vast literature exists surrounding MRONJ, many studies have small participant numbers and are heterogeneous in design, leaving unanswered questions and making evidence-based practice challenging.</p><p><strong>Objective: </strong>Provide an overview of recent MRONJ incidence data, over a 5-year period, identify potential issues in reporting MRONJ cases and propose changes for future reporting.</p><p><strong>Eligibility criteria: </strong>Studies with original data regarding MRONJ incidence published from 2015 to 2020.</p><p><strong>Sources of evidence: </strong>A search was conducted on MEDLINE Ovid, the National Library of Medicine's bibliographic database, using a combination of medical subject headings (MeSH) and free text terms and run on 29 April 2021.</p><p><strong>Charting method: </strong>Each title was hand-screened, and the abstract/article in full was reviewed to establish suitability for inclusion by two authors. Data extraction by two reviewers included author, year of publication, study design, population-cancer/osteoporosis/both/other, description of population, sampling method, exclusion criteria, single centre Y/N, reported rate of MRONJ cases/number of participants, details of diagnosis and diagnostic criteria, duration of follow-up and location of study.</p><p><strong>Results: </strong>The initial search returned 1186 titles, detailed screening and inclusion of additions resulted in 92 articles for data extraction. Mean incidence of MRONJ across all studies was 4.34% (median 2.42%, range 0% to 31.80%). The mean incidence based on patient group was oncology 6.22% (32 954 participants), osteoporosis 0.58% (498 443 participants), oncology and osteoporosis 7.21% (54 7651 participants) and other, including autoimmune, inflammatory and other bone conditions, 2.55% (4487 participants). Further analysis showed incidence influenced by study size (>500 participants), diagnostic criteria used, location of study and other factors.</p><p><strong>Conclusion: </strong>Heterogeneity in studies reporting MRONJ incidence impacts results and conclusions. Standardised, contemporaneous reporting of MRONJ cases would eliminate this variation and provide valuable insight into the epidemiology, natural history and outcomes of these patients, supporting evidence-based management and service provision of patients affected.</p>","PeriodicalId":101362,"journal":{"name":"BMJ public health","volume":"3 1","pages":"e002009"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973752/pdf/","citationCount":"0","resultStr":"{\"title\":\"The issue with incidence: a scoping review of reported medication-related osteonecrosis of the jaws (MRONJ) incidence around the globe.\",\"authors\":\"Ailish Suzanne Emuss Clark, Anne-Marie Glenny\",\"doi\":\"10.1136/bmjph-2024-002009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Medication-related osteonecrosis of the jaws (MRONJ) can be a debilitating condition which is challenging to manage. While vast literature exists surrounding MRONJ, many studies have small participant numbers and are heterogeneous in design, leaving unanswered questions and making evidence-based practice challenging.</p><p><strong>Objective: </strong>Provide an overview of recent MRONJ incidence data, over a 5-year period, identify potential issues in reporting MRONJ cases and propose changes for future reporting.</p><p><strong>Eligibility criteria: </strong>Studies with original data regarding MRONJ incidence published from 2015 to 2020.</p><p><strong>Sources of evidence: </strong>A search was conducted on MEDLINE Ovid, the National Library of Medicine's bibliographic database, using a combination of medical subject headings (MeSH) and free text terms and run on 29 April 2021.</p><p><strong>Charting method: </strong>Each title was hand-screened, and the abstract/article in full was reviewed to establish suitability for inclusion by two authors. Data extraction by two reviewers included author, year of publication, study design, population-cancer/osteoporosis/both/other, description of population, sampling method, exclusion criteria, single centre Y/N, reported rate of MRONJ cases/number of participants, details of diagnosis and diagnostic criteria, duration of follow-up and location of study.</p><p><strong>Results: </strong>The initial search returned 1186 titles, detailed screening and inclusion of additions resulted in 92 articles for data extraction. Mean incidence of MRONJ across all studies was 4.34% (median 2.42%, range 0% to 31.80%). The mean incidence based on patient group was oncology 6.22% (32 954 participants), osteoporosis 0.58% (498 443 participants), oncology and osteoporosis 7.21% (54 7651 participants) and other, including autoimmune, inflammatory and other bone conditions, 2.55% (4487 participants). Further analysis showed incidence influenced by study size (>500 participants), diagnostic criteria used, location of study and other factors.</p><p><strong>Conclusion: </strong>Heterogeneity in studies reporting MRONJ incidence impacts results and conclusions. Standardised, contemporaneous reporting of MRONJ cases would eliminate this variation and provide valuable insight into the epidemiology, natural history and outcomes of these patients, supporting evidence-based management and service provision of patients affected.</p>\",\"PeriodicalId\":101362,\"journal\":{\"name\":\"BMJ public health\",\"volume\":\"3 1\",\"pages\":\"e002009\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973752/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ public health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjph-2024-002009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjph-2024-002009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:药物相关性颌骨骨坏死(MRONJ)是一种具有挑战性的衰弱性疾病。虽然有大量关于MRONJ的文献,但许多研究的参与者人数很少,设计也不一样,留下了未解的问题,使循证实践具有挑战性。目的:概述最近5年MRONJ发病率数据,确定报告MRONJ病例的潜在问题,并提出未来报告的变化建议。入选标准:2015年至2020年发表的MRONJ发病率原始数据的研究。证据来源:在MEDLINE Ovid(国家医学图书馆的书目数据库)上进行了搜索,使用医学主题标题(MeSH)和免费文本术语的组合,于2021年4月29日运行。图表法:每个标题都是手工筛选的,摘要/文章全文由两位作者审查,以确定是否适合纳入。两位审稿人提取的资料包括作者、发表年份、研究设计、人群-癌症/骨质疏松/两者/其他、人群描述、抽样方法、排除标准、单中心Y/N、MRONJ病例报告率/参与者人数、诊断和诊断标准的详细信息、随访时间和研究地点。结果:最初的搜索返回了1186个标题,详细的筛选和添加结果为92篇文章进行数据提取。所有研究中MRONJ的平均发生率为4.34%(中位数为2.42%,范围为0%至31.80%)。基于患者组的平均发病率为肿瘤学6.22%(32 954名参与者),骨质疏松症0.58%(498 443名参与者),肿瘤学和骨质疏松症7.21%(54 7651名参与者),其他包括自身免疫、炎症和其他骨骼疾病2.55%(4487名参与者)。进一步分析显示,发病率受研究规模(500名参与者)、使用的诊断标准、研究地点和其他因素的影响。结论:报告MRONJ发病率的研究的异质性影响结果和结论。MRONJ病例的标准化、同步报告将消除这种差异,并为这些患者的流行病学、自然病史和结果提供有价值的见解,支持受影响患者的循证管理和服务提供。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The issue with incidence: a scoping review of reported medication-related osteonecrosis of the jaws (MRONJ) incidence around the globe.

Background: Medication-related osteonecrosis of the jaws (MRONJ) can be a debilitating condition which is challenging to manage. While vast literature exists surrounding MRONJ, many studies have small participant numbers and are heterogeneous in design, leaving unanswered questions and making evidence-based practice challenging.

Objective: Provide an overview of recent MRONJ incidence data, over a 5-year period, identify potential issues in reporting MRONJ cases and propose changes for future reporting.

Eligibility criteria: Studies with original data regarding MRONJ incidence published from 2015 to 2020.

Sources of evidence: A search was conducted on MEDLINE Ovid, the National Library of Medicine's bibliographic database, using a combination of medical subject headings (MeSH) and free text terms and run on 29 April 2021.

Charting method: Each title was hand-screened, and the abstract/article in full was reviewed to establish suitability for inclusion by two authors. Data extraction by two reviewers included author, year of publication, study design, population-cancer/osteoporosis/both/other, description of population, sampling method, exclusion criteria, single centre Y/N, reported rate of MRONJ cases/number of participants, details of diagnosis and diagnostic criteria, duration of follow-up and location of study.

Results: The initial search returned 1186 titles, detailed screening and inclusion of additions resulted in 92 articles for data extraction. Mean incidence of MRONJ across all studies was 4.34% (median 2.42%, range 0% to 31.80%). The mean incidence based on patient group was oncology 6.22% (32 954 participants), osteoporosis 0.58% (498 443 participants), oncology and osteoporosis 7.21% (54 7651 participants) and other, including autoimmune, inflammatory and other bone conditions, 2.55% (4487 participants). Further analysis showed incidence influenced by study size (>500 participants), diagnostic criteria used, location of study and other factors.

Conclusion: Heterogeneity in studies reporting MRONJ incidence impacts results and conclusions. Standardised, contemporaneous reporting of MRONJ cases would eliminate this variation and provide valuable insight into the epidemiology, natural history and outcomes of these patients, supporting evidence-based management and service provision of patients affected.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信